Management and treatment of the HCV-infected kidney transplant patient

Area of Science:

• Nephrology
• Hepatology
• Transplantation

Background:

• Hepatitis C virus (HCV) infection is more prevalent in end-stage kidney disease (ESKD) patients.
• HCV infection is a significant determinant of adverse outcomes in ESKD patients.

Purpose of the Study:

• To review hepatic and nonhepatic manifestations of HCV in kidney transplant recipients.
• To discuss management and treatment strategies for HCV in kidney transplant patients.
• To highlight the role of direct-acting antivirals (DAAs) in optimizing transplant outcomes.

Main Methods:

• Literature review of studies on HCV in kidney transplant patients.
• Analysis of hepatic and nonhepatic manifestations.
• Evaluation of current and emerging treatment strategies, including DAAs.

Main Results:

• DAAs are transforming the management of HCV in kidney transplant candidates and recipients.
• Effective HCV treatment with DAAs can potentially reduce morbidity and mortality associated with kidney transplantation.
• Optimizing HCV management is crucial for improving long-term transplant success.

Conclusions:

• Direct-acting antiviral therapy represents a paradigm shift in managing hepatitis C virus in kidney transplant populations.
• Addressing HCV manifestations and implementing effective treatment strategies are vital for enhancing patient outcomes post-transplant.